Shoulder Innovations has secured $40m in a Series E equity financing round, to mainly progress the commercialisation of its InSet Total Shoulder and Reverse Shoulder Arthroplasty Systems.
The proceeds from the round will also be utilised for general corporate activities and supporting the development of a new product.
Related: 4C Medical secures $175m funding round led by Boston Scientific to support TMVR tech
Current investor US Venture Partners led the funding round, which also saw contributions from current investors such as Gilde Healthcare Partners, Aperture Venture Partners, and Gilmartin Capital, along with Sectoral Asset Management and Arboretum Ventures.
Shoulder Innovations CEO Rob Ball said: “Over recent years, we have significantly expanded our product line, strengthened our sales organisation, and emerged as a pure-play leader in shoulder arthroplasty.
“We appreciate the support of our new and existing investors and see this financing as well-timed as we hone our focus on accelerating commercial momentum and advance our mission of enabling best-in-class outcomes for shoulder specialists and their patients.”
The company noted that InSet Glenoid technology is tailored to mitigate glenoid loosening, the primary cause of failure in total shoulder arthroplasty (TSA).
By positioning the implant within a sclerotic bone pocket, the InSet Glenoid claims to decrease mechanical stress at the interface of bone and implant, which has been demonstrated through finite element analysis to lessen “rocking horse” stresses by 87%.
This method aids surgeons in improving the shoulder implants’ longevity.
According to the company, the InSet Reverse System provides a reproducible solution for complex shoulder condition management while maintaining biomechanical integrity.
Shoulder Innovations focuses on advancing shoulder arthroplasty solutions and aims to enhance patient care and minimise healthcare expenses.
